AbCellera Biologics Inc.
ABCLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AbCellera Biologics Inc. focuses on Biotechnology services and products. AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. At a $1.97B market cap, AbCellera Biologics Inc. ranks as a small-cap company within healthcare. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
Market Cap
$1.97B
Beta
1.15
P/E (TTM)
—
P/E (Fwd)
-9.17
EPS (TTM)
$-0.50
EPS (Fwd)
$-0.70
ROE
-14.7%
ROA
-10.0%
Cash
$504.7M
Total Debt
$140.2M
Free CF
-$114.0M
52W Change
44.3%
Annual Financials
Cash vs Debt
With $504.7M in cash and $140.2M in debt, ABCL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$114.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -14.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $485.4M (2022) to $75.1M (2025), a 85% decline worth watching.
With cash comfortably exceeding debt, ABCL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AbCellera Biologics Inc. and its sector.